♟️ Thursday 20 November 2025 Thu, 20 Nov 2025
36 Move Signals
Hansen Technologies Accelerates Growth with Digitalk Acquisition and AI Innovation
Hansen Technologies reported robust FY25 results driven by double-digit revenue growth, strategic contract wins, and a transformative acquisition of UK-based Digitalk. The company’s integration of AI and sustainability initiatives underpin a confident outlook for sustained growth.
20 Nov
Sophie Babbage
Dataworks Dominates Regulated Gaming with Market-Leading Self-Exclusion Tech
Dataworks Limited solidifies its leadership in regulated gaming technology with its Centralised Self-Exclusion platform, backed by major government contracts and a robust growth pipeline.
20 Nov
Sophie Babbage
Apiam’s Strategic Reset Spurs Q1 Growth Ahead of $0.87/share Acquisition Deal
Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.
20 Nov
Ada Torres
NexGen Energy Advances Rook I Project with Key Federal Approval Hearing
NexGen Energy has entered the final phase of federal regulatory approval for its flagship Rook I uranium project, marking a pivotal step toward construction and production. This follows over a decade of environmental assessments and provincial approvals.
20 Nov
Maxwell Dee
Lake Resources Advances Kachi Project with Breakthrough Lithium Tech and Strong Market Momentum
Lake Resources N.L. reports significant progress on its Kachi lithium project, unveiling enhanced project economics and next-generation lithium extraction technology amid a bullish lithium market and supportive Argentine political climate.
20 Nov
Maxwell Dee
Lake Resources Elevates Kachi Lithium Project with Major Resource and Cost Gains
Lake Resources has announced a significant upgrade to its Kachi Lithium Brine Project, boosting resources and cutting costs amid a strengthening lithium market and supportive Argentine policies.
20 Nov
Maxwell Dee
Worley Unveils $269M Buy-Back and Growth Plans Amid Strong FY2025 Results
Worley Limited reported solid financial results for FY2025, highlighted by disciplined capital management including a $269 million share buy-back and a strong focus on sustainability. The company outlined strategic priorities and anticipates moderate growth in FY2026 with a new growth strategy to be revealed next year.
20 Nov
Maxwell Dee
AACo Doubles Operating Profit on Beef Sales and Strategic Growth Moves
Australian Agricultural Company Limited (AACo) has reported a record first-half operating profit of $39.8 million, nearly doubling from the previous year, driven by higher beef prices and strategic live cattle sales. The company’s investments in genetics, carbon projects, and global market expansion set a strong foundation for future growth.
20 Nov
Ada Torres
AACo Nearly Doubles Operating Profit in Strong FY26 Half-Year Results
Australian Agricultural Company Limited (AACo) has reported robust growth in its FY26 half-year results, with significant increases in operating profit, statutory EBITDA, and cattle sales driving the upbeat performance.
20 Nov
Ada Torres
Turners Automotive Group Drives Record Profit Growth Amid Market Challenges
Turners Automotive Group has delivered a record first-half profit for FY26, driven by strong growth in its Finance and Insurance divisions despite ongoing supply constraints in the used vehicle market. The company also raised its interim dividend, signalling confidence in its diversified business model and capital management strategy.
20 Nov
Victor Sage
AFT Pharmaceuticals Accelerates Global Growth with 33% Revenue Surge in 1H FY26
AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.
20 Nov
Ada Torres
AFT Pharmaceuticals Accelerates Growth with 33% Revenue Surge and Global Expansion
AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.
20 Nov
Victor Sage